pdufa
.bio
Calendar
Decisions
Research
Home
›
Decisions
› ASND 2026-02-27
ASND
FDA decision
— Feb 27, 2026
✓ APPROVED
Ascendis Pharma A/S — YUVIWEL (navepegritide) · Achondroplasia.
Run-up into the decision (T-120 → T+5)
PDUFA 2/27/26
$238.8
$189.74
9/12/25
Daily close, T-120 (9/12/25) through T+5. Run-up high $238.8 on 1/28/26, low $189.74 on 10/2/25 (T-120 to T-1). FDA decision 2/27/26. Historical price action, not a forecast.
Key facts
FDA decision date
2026-02-27
Outcome
Approved
Drug / candidate
YUVIWEL (navepegritide)
Company
Ascendis Pharma A/S
120-day run-up (T-120→T-1)
+11.2%
Not affiliated with or endorsed by the FDA.
Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio